Wednesday, February 06, 2013 6:08 pm
News Summary: Elan, Biogen revise Tysabri deal
By The Associated Press
CAPITAL IDEA: The drug developers currently split earnings from Tysabri, but Elan said the new deal will give it capital for investing and growing its business.
DIRECT INJECT: Tysabri is a drug taken intravenously once a month to combat to treat a form of multiple sclerosis that cycles between stages of relapse and remission.